ATOS Skyrockets, BPMX Gets "Going Concern" Warning, Respite For KPTI

Today’s Daily Dose brings you news about the positive progress of Atossa Genetics’ Oral Endoxifen as a post-mastectomy treatment for breast cancer; BioLife Solutions’ stellar fourth-quarter financial results; BioPharmX Corp’s anticipated milestones in 2019; revised FDA decision date of Karyopharm’s Selinexor; and clinical trial catalysts of SCYNEXIS. Read on… Shares of Atossa Genetics Inc. (ATOS) jumped more than 350% on […]

Read more